GlassScriptPhysician profile
Adam Nomberg
NPI 1851393847
$2,281.96
in general payments reported to CMS, 2019-2025
10 companies · $616 in 2025
The $616 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $288 · 2021: $209 · 2022: $167 · 2023: $302 · 2024: $402 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.67 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $897.51 | 2019-2025 | Total30, Precision7, Precision 1 |
| Abbvie INC. | $480.13 | 2022-2025 | |
| Allergan, INC. | $292.03 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $148.07 | 2024 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $119.24 | 2019 | |
| Bausch & Lomb Americas INC. | $116.83 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $98.12 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $47.74 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $43.03 | 2023 | Cequa |
| Johnson & Johnson Vision Care, INC. | $39.26 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Nomberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.